Sign inJoin waitlistJoin the waitlist

Rajni Agarwal

Clinical Director, Pediatric Stem Cell Transplantation · Stanford Health Care

Credentials: · · ·

History

Pediatric Stem Cell Transplantation · Stanford Health Care
Present
Pediatric Stem Cell Transplant · Stanford Health Care
Present
Pediatric Stem Cell Transplantation · Stanford Health Care
Present

Hematology and Medical Oncology
1995–1998
Pediatrics
Cincinnati Children's Hospital Medical Center
1992–1995
MGM Medical College (1983) India
1979–1983
MGM Medical College (1983) India
1978–1981

Research

Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010-2017
PEDIATRICS · 2019 · 158 citations
Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years
Journal of Allergy and Clinical Immunology · 2013 · 156 citations
Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy
Blood · 2006 · 131 citations

Christopher Dvorak
9 papers · 1 as a fellow
Kenneth Weinberg
9 papers
Matthew Porteus
7 papers · 3 as a resident
Alice Bertaina
6 papers
Sandhya Kharbanda
5 papers
Sarah Donaldson
5 papers
Ami Shah
4 papers
Donald Kohn
4 papers
DS
David Shyr
3 papers
Maria Roncarolo
3 papers
NK
Neena Kapoor
3 papers
Susan Hiniker
3 papers · 1 as a resident

Clinical trials

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab
Principal investigator · Recruiting · Phase 1, Phase 2
Porteus, Matthew, MD
2021–2028
Gene Therapy for Fanconi Anemia, Complementation Group A
Principal investigator · Active not recruiting · Phase 2
Rocket Pharmaceuticals Inc.
2020–2026
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
Principal investigator · Terminated · Phase 1
Roncarolo, Maria Grazia, MD
2017–2021
JSP191 Antibody Targeting Conditioning in SCID Patients
Principal investigator · Terminated · Phase 1, Phase 2
Jasper Therapeutics, Inc.
2017–2025